ROSSARI2023-04-012023-06-30 ROSSARI2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member ROSSARI2023-06-30 ROSSARI2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543213 ROSSARI NOTLISTED Rossari Biotech Limited Equity 2023-04-01 2024-03-31 2023-07-29 2023-07-21 INR Millions First quarter 13:10:00 14:26:00 2023-07-29 2023-07-29 Not applicable Single segment Manufacturing of Specialty Chemicals for Textile, Home and Personal Care, Performance Chemicals and Animal Health and Nutrition industries 2023-04-01 2023-06-30 Unaudited Consolidated 4106060000.00 21900000.00 4127960000.00 2720720000.00 414930000.00 -240540000.00 245210000.00 63160000.00 141140000.00 388280000.00 3732900000.00 395060000.00 0.00 395060000.00 131860000.00 -29480000.00 102380000.00 0.00 292680000.00 0.00 0.00 0.00 -490000.00 292190000.00 850000.00 293040000.00 292190000.00 293040000.00 0.00 110310000.00 2 5.30 5.28 0.00 0.00 5.30 5.28 Notes:1.The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 29th July, 2023.2.The consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) 34 on Interim Financial Reporting as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.3.The Group deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Company consideres it as one operating segment. 4.The figures for the quarter ended 31st March 2023 are balancing figures between the audited figures in respect of the full financial year and the published year to date figures for the nine months period ended 31st December, 2022.5.During the quarter ended 30th June, 2023, the Holding Company has acquired balance 16% stake in its subsidiary, Tristar Intermediates Private Limited for an aggregate consideration of Rs. 169.33 million from the existing shareholders. For ROSSARI BIOTECH LIMITED EDWARD MENEZES Executive Chairman DIN:00149205 Place : Mumbai Date :29.07.2023 Other Expenses 388280000.00 Remeasurements of the defined benefit plans 1130000.00 1130000.00 280000.00